Evidence map›Paper›PMID 29898731›Full record

ArticleWorld journal of surgical oncology2018

Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways.

Ashley B Ward, Hina Mir, Neeraj Kapur, Dominique N Gales, Patrick P Carriere, Shailesh Singh

Open access · goldAbstract read
In one paragraph

Article in World journal of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 1 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed, 1 synthesis or guideline pooled it, 243 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Article
  5. Quercetin ReducesInternational journal of molecular sciences · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Evaluation of the Pharmacological Potential ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  10. Review
  11. Drug design, development and therapy · 2026
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Antioxidant Intervention Against Microplastic Hazards.Antioxidants (Basel, Switzerland) · 2025
    Review
  19. Review
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ashley B WardDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Hina MirDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Neeraj KapurDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Dominique N GalesDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Patrick P CarriereDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.
Shailesh SinghDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA. shsingh@msm.edu.ORCID http://orcid.org/0000-0002-5051-4734
Morehouse School of Medicine · US

Funding

Research Training & Career Development ProgramU54CA118638 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI Desiree Avia Rivers · 2005 to 2026
$22.7M
Role of CCL25-CCR9 in Prostate CancerSC1CA180212 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI SINGH, SHAILESH · 2013 to 2017
$1.8M
Role of chemokine receptor in disparities associated with prostate cancer progresU01CA179701 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI SINGH, SHAILESH · 2013 to 2017
$822k
Prostate Cancer Chemoprevention using a Natural AgentR21CA169716 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI SINGH, SHAILESH · 2013 to 2014
$334k
National Cancer Institute CA118638National Cancer Institute CA169716National Cancer Institute CA179701National Cancer Institute CA180212NCI NIH HHS R21 CA169716NCI NIH HHS SC1 CA180212NCI NIH HHS U01 CA179701NCI NIH HHS U54 CA118638
6 · The paper itself

Abstract

backgroundDespite recent advances in diagnosis and treatment, prostate cancer (PCa) remains the leading cause of cancer-related deaths in men. Current treatments offered in the clinics are often toxic and have severe side effects. Hence, to treat and manage PCa, new agents with fewer side effects or having potential to reduce side effects of conventional therapy are needed. In this study, we show anti-cancer effects of quercetin, an abundant bioflavonoid commonly used to treat prostatitis, and defined quercetin-induced cellular and molecular changes leading to PCa cell death.

methodsCell viability was assessed using MTT. Cell death mode, mitochondrial outer membrane potential, and oxidative stress levels were determined by flow cytometry using Annexin V-7 AAD dual staining kit, JC-1 dye, and ROS detection kit, respectively. Antibody microarray and western blot were used to delineate the molecular changes induced by quercetin.

resultsPCa cells treated with various concentrations of quercetin showed time- and dose-dependent decrease in cell viability compared to controls, without affecting normal prostate epithelial cells. Quercetin led to apoptotic and necrotic cell death in PCa cells by affecting the mitochondrial integrity and disturbing the ROS homeostasis depending upon the genetic makeup and oxidative status of the cells. LNCaP and PC-3 cells that have an oxidative cellular environment showed ROS quenching after quercetin treatment while DU-145 showed rise in ROS levels despite having a highly reductive environment. Opposing effects of quercetin were also observed on the pro-survival pathways of PCa cells. PCa cells with mutated p53 (DU-145) and increased ROS showed significant reduction in the activation of pro-survival Akt pathway while Raf/MEK were activated in response to quercetin. PC-3 cells lacking p53 and PTEN with reduced ROS levels showed significant activation of Akt and NF-κB pathway. Although some of these changes are commonly associated with oncogenic response, the cumulative effect of these alterations is PCa cell death.

conclusionsOur results demonstrated quercetin exerts its anti-cancer effects by modulating ROS, Akt, and NF-κB pathways. Quercetin could be used as a chemopreventive option as well as in combination with chemotherapeutic drugs to improve clinical outcomes of PCa patients.

Indexed as

Antineoplastic AgentsAntioxidantsApoptosisCell Line, TumorCell SurvivalHumansMalePrognosisProstatic NeoplasmsQuercetinAntineoplastic AgentsAntioxidantsQuercetinApoptosisBioflavonoidCell survivalChemopreventionProstate cancerQuercetin

Identifiers

PMID29898731
PMCPMC6001031
OpenAlexW2808532182

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.